Metropolis Healthcare

    METROPOLIS
    Pharma
    ₹564.30
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹11,711 Cr

    P/E
    52.35
    Day range
    ₹561.50 – ₹576.80
    52-week range
    ₹412.25 – ₹609.05
    Volume
    1.68 L
    Open
    ₹567.00
    Prev close
    ₹567.00

    Latest results · Q2 FY27(consolidated)Revenue ₹497 Cr+15.8%Profit ₹75 Cr+42.7%Margin 15.2%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter pledge went up

      1.21% of promoter shares pledged, up from 1.18% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 66 / 100

    Factor percentiles

    Value40
    Quality67
    Momentum69
    Low volatility88

    Derived metrics

    Earn. yield
    1.9%
    Graham no.
    ₹139.51
    vs Graham
    -75.3%
    ROE ÷ P/B
    1.9%
    12-1 mom.
    +9.6%
    Return / vol
    0.57
    Magic Formula
    #416
    Piotroski
    6/6
    FCF yield
    2.6%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Metropolis HealthcareMETROPOLIS₹11,711 Cr52.357.2613.4%18.0%27.0%0.16+15.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 6h ago

    Headlines about Metropolis Healthcare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    51.6
    Price / Book
    7.13
    ROE (FY26)
    13.4%
    ROCE (latest year)
    18%
    Dividend yield
    0.35%

    Moving averages (NSE)

    20-day
    ₹558.07
    Price above
    50-day
    ₹561.11
    Price above
    200-day
    ₹526.97
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +12.8%
    Profit 3Y CAGR
    +10.1%
    Revenue YoY (Sep 2026)
    +15.9%
    Profit YoY (Sep 2026)
    +41.5%
    Operating margin
    27.0%
    Net margin
    15.1%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 20 Mar 2026: earlier bars are per pre-bonus share.

    FY21FY22FY23FY24FY25FY26₹0₹2₹4₹6₹8

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales291331313350323345386429406425450497
    Expenses226251235260251283296321311317339363
    Operating Profit6580799072629010895108111134
    OPM %22%24%25%26%22%18%23%25%23%25%25%27%
    Other Income232337810858
    Interest565555566867
    Depreciation252626272829313232393233
    Profit before tax3751516142366171577078102
    Tax %26%28%25%24%26%19%26%26%26%27%27%26%
    Net Profit273738473129455342515775
    EPS in Rs₹1.33₹1.78₹1.85₹2.27₹1.53₹1.41₹2.17₹2.54₹2.00₹2.46₹2.73₹3.63

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days38

    -7 days since Mar 2021

    Inventory Days51

    -8 days since Mar 2021

    Days Payable146

    -14 days since Mar 2021

    Cash Conversion Cycle-57

    -1 days since Mar 2021

    Working Capital Days-15

    -6 days since Mar 2021

    Strengths, risks & growth

    Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 7.26 times its book value
    • Promoter holding has decreased over last quarter: -1.04%
    • The company has delivered a poor sales growth of 10.5% over past five years.
    • Company has a low return on equity of 12.5% over last 3 years.

    Compounded Sales Growth

    10 Years
    +13%
    5 Years
    +11%
    3 Years
    +13%
    TTM
    +20%

    Compounded Profit Growth

    10 Years
    +11%
    5 Years
    +1%
    3 Years
    +11%
    TTM
    +46%

    Stock Price CAGR

    10 Years
    —
    5 Years
    -6%
    3 Years
    +12%
    1 Year
    +16%

    Return on Equity

    10 Years
    +19%
    5 Years
    +15%
    3 Years
    +13%
    Last Year
    +14%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter48.87%48.86%48.86%47.82%-1.04 pp
    FII11.68%10.43%11.03%11.67%+0.64 pp
    DII34.73%35.80%35.12%35.49%+0.37 pp
    Public4.69%4.92%5.00%5.02%+0.02 pp

    Filed with NSE for Sept 2026: promoters 47.82%, public 52.18%

    Analysts & fund holdings

    79%
    79% recommend buy
    19 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E52.3 vs 45.2
    Sector P/B6.05
    Beta0.83

    Who holds the shares, quarter by quarter

    Mutual funds 33.09% (+0.42 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters47.8%
    • Foreign institutions11.7%
    • Mutual funds33.1%
    • Insurance2.0%
    • Other domestic institutions0.4%
    • Retail3.3%
    • Others1.7%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Kotak Small Cap Fund3.12%1.94%-0.02 pp
    HDFC Focused Fund3.07%1.38%-0.04 pp
    HDFC Flexi Cap Fund2.93%0.32%-0.02 pp
    Franklin India Small Cap Fund2.30%2.06%+0.30 pp
    Nippon India Small Cap Fund2.10%0.33%-0.01 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.

    Computed

    Risk

    Volatility (1Y)
    29.4%
    Downside volatility
    26.5%
    Worst 5% of days
    2.7%
    Average of that tail
    3.6%
    Max drawdown (1Y)
    20.9%
    Below its peak
    6.3%

    Against the market

    Beta vs Nifty 50
    0.41
    Correlation
    0.19
    Relative strength (3M)
    -1.4%
    ATR (14)
    3.3%

    Return

    Return 1M
    +6.4%
    Return 3M
    +2.5%
    Return 6M
    +11.2%
    Return 1Y
    +16.7%
    vs 200-day average
    +7.1%

    Momentum

    RSI (14)
    52.0
    MACD histogram
    0.99
    Stochastic %K
    46.4
    ADX (14)
    27.9
    +DI / −DI
    19.7 / 12.2
    Money flow index
    71.4

    Participation

    Delivery (20d avg)
    53.8%
    vs its 60-day baseline
    -1.1 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.2%
    52-week position
    79 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    6 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹300 Cr
    FCF yield
    2.6%
    Cash conversion
    1.83
    Accruals ratio
    -0.075
    Net debt
    ₹199 Cr
    Net debt / equity
    0.12
    EV / sales
    6.70
    Capex intensity
    3.1%
    Revenue CAGR
    27.4%
    Profit CAGR
    88.1%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹118 Cr
    0 buys · ₹0
    2 sells · ₹118 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Metz Advisory LLP
    Promoter · Market Sale
    Sell10,50,000₹59.2 Cr13 Aug 2026
    Duru Shah Family Trust
    Promoter Group · Market Sale
    Sell10,50,000₹59.2 Cr13 Aug 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1 Per Share

      9 Nov 2026
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1 Per Share

      19 May 2026
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 3:1

      20 Mar 2026
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      11 Nov 2025
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      17 Nov 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      10 Aug 2023
      ex-date
    • dividend
      ₹8.00

      Interim Dividend - Rs 8 Per Share

      23 Feb 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      8 Aug 2022
      ex-date
    • dividend
      ₹8.00

      Interim Dividend - Rs. 8 Per Share

      21 Feb 2022
      ex-date
    • dividend
      ₹8.00

      Interim Dividend - Rs 8 Per Share

      17 Feb 2021
      ex-date
    • dividend
      ₹8.00

      Interim Dividend - Rs 8 Per Share

      13 Feb 2020
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026

    Company Update
    Business Update For Q2FY27

    Business update for Q2FY27

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of 66,312 equity shares under the Metropolis- Restrictive Stock Unit Plan, 2020

    Company Update
    Announcement under Regulation 30 (LODR)-Restructuring

    Disclosure under Regulation 30 of SEBI Listing Regulations

    Insider Trading / SAST
    Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Franklin Templeton Mutual Fund

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Investors & Analyst Meet held on Thursday, August 27, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio recording of the Investors & Analyst Meet

    Company Update
    Disclosure Under Regulation 30 Of SEBI Listing Regulations

    Disclosure under Regulation 30 of SEBI Listing Regulations

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation

    Company Update
    Announcement under Regulation 30 (LODR)-Restructuring

    Disclosure under Regulation 30 of SEBI Listing Regulations

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of Analyst / Institutional Investor Meeting

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer's Report for the 26th Annual General Meeting

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the 26th Annual General Meeting of the Company

    Filed with BSE (scrip 542650); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Metropolis Healthcare: common questions

    Answered from the figures on this page.

    Metropolis Healthcare last traded at ₹564.30 (NSE, as of 18 Nov 2026). The last session moved it down 0.48%.

    Metropolis Healthcare is valued at about ₹11,711 crore (NSE, as of 18 Nov 2026).

    Metropolis Healthcare trades at a price-to-earnings ratio of 52.35 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Metropolis Healthcare has traded between ₹412.25 and ₹609.05 over the past 52 weeks, to 18 Nov 2026. It is currently 77% of the way up that range.

    Metropolis Healthcare (METROPOLIS) is classified under Pharma on this site's screener.